97 related articles for article (PubMed ID: 21645832)
1. [Positron emission tomography with 18F-FDG and cancer response to chemotherapy].
van Ruychevelt V; Garcia C; Meert AP; Berghmans T; Paesmans M; Flamen P; Sculier JP
Rev Mal Respir; 2011 May; 28(5):618-25. PubMed ID: 21645832
[TBL] [Abstract][Full Text] [Related]
2. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
[TBL] [Abstract][Full Text] [Related]
5. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer.
Banna GL; Anile G; Russo G; Vigneri P; Castaing M; Nicolosi M; Strano S; Gieri S; Spina R; Patanè D; Calcara G; Fraggetta F; Marletta F; Stefano A; Ippolito M
Oncology; 2017; 92(1):39-47. PubMed ID: 27832654
[TBL] [Abstract][Full Text] [Related]
6. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
7. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
8. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.
Ordu C; Selcuk NA; Akosman C; Eren OO; Altunok EC; Toklu T; Oyan B
Asian Pac J Cancer Prev; 2015; 16(1):321-6. PubMed ID: 25640373
[TBL] [Abstract][Full Text] [Related]
13. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
15. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
17. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
[TBL] [Abstract][Full Text] [Related]
20. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
Tanvetyanon T; Eikman EA; Sommers E; Robinson L; Boulware D; Bepler G
J Clin Oncol; 2008 Oct; 26(28):4610-6. PubMed ID: 18824709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
